We are a development stage specialty pharmaceutical company focused on the development of late-stage (PH II and PH III) prescription drugs for gastrointestinal disorders, specifically, hemorrhoids, anal fissures and fecal incontinence.

We believe that hemorrhoids, anal fissures and fecal incontinence each represent a significant unmet medical need.

While we estimate that there currently are approximately 12.5 million Americans suffering from hemorrhoids, 7 million from fecal incontinence and over 4 million from anal fissures, we are not aware of any U.S. Food and Drug Administration, or FDA, approved prescription treatments for these conditions

Our product candidate portfolio consists of three late-stage drugs intended to treat these conditions, for which, to our knowledge, there are no currently approved prescription products in the US:

• VEN 309, iferanserin cream for the treatment of symptomatic hemorrhoids, a new chemical entity, or NCE, ready to enter PH III studies
• VEN 307,Diltiazem cream, a commonly used drug used orally for hypertension and angina, formulated topically for the treatment of anal fissures, ready to enter Phase III studies
• VEN 308, Phenylephrine gel, a common ingredient in cough and cold medicines, formulated topically for the treatment of fecal incontinence ; ready to enter PH IIB studies